I would like to start off by saying that Candidiasis has several names, which are: Candida yeast overgrowth or Thrush, Candida Albicans or Candida Tropicalis. Candidiasis is a global health problem. Research indicates that more than 80% of people in industrialized nations are now infected with Candidiasis. I think that information in this article can help you live a much healthier, happier life.

What is Candida?

Candida Albicans: yeast like fungal organism found in small amounts in the normal human intestinal tract. normally kept in check by the body’s own helpful bacteria, C Albicans can increase in numbers when this balance is disturbed to cause candidiasis of the intestinal tract, or yeast infections of other parts of the body. C. Albicans can cause thrush. our immune system is designed to defend us from illness. several factors can bring about the onset of candidiasis: excessive use of antibiotics or steroids, oral contraceptives, overly-acidic ph levels from processed foods and stress, hormone imbalances, exposure to environmental toxins (often molds) and chronic illness.

When our immune systems are compromised, normal yeast present in our bodies, called Candida, can morph from being beneficial yeast into a harmful fungus. this fungal yeast can quickly grow out of the normal balance that nature intended and overwhelm the beneficial flora (acidophilus type of bacteria) that ordinarily keeps natural yeast levels in check. The name of this yeast overgrowth is called candidiasis. this new fungal form of yeast develops rhizoid or long burrowing legs that can attach onto and penetrate the mucus membranes in the intestinal tract and cause serious bowel pain. Over time the morphed fungal yeast may burrow right through the intestinal wall. this condition is called Leaky Gut Syndrome, allows partially digested proteins and the yeast itself to travel into the bloodstream where they become toxins. The yeast infection can permeate through the entire body, if this occurs then you have a system-wide or systemic candidiasis.

What are symptoms of Candida?

-Bloating and indigestion

-Oral thrush (white film in mouth or on tongue)

-Hair loss and vision problems

-Weight loss or weight gain and the inability to change it

-Rashes inside the ears or around the groin area

-Fungus on the finger or toenails

-Chronic sinus drainage

Go to the bottom of this article and click on the link for more information about other health related diseases.

Disclaimer

The information provided herein should not be construed as a health-care diagnosis, treatment regimen or any other prescribed health-care advice or instruction. The information is provided with the understanding that the publisher is not engaged in the practice of medicine or any other health-care profession and does not enter into a health-care practioner/ patient relationship with its readers. The publisher does not advise or recommend to its readers treatment or action with regard to matters relating to their health or well being other than to suggest that readers consult appropriate health-care professionals in such matters. no action should be taken based solely on the content of this publication.

The information and opinions provided herein are believed to be accurate and sound at the time of this publication based on the best judgment available to the authors. however, readers who rely on information in this publication to replace the advice of health-care professionals, or who fail to consult with health-care professionals assume all risks of such conduct. The publisher isn’t responsible for errors or omissions. The Food and Drug Administration have not evaluated these statements. these products aren’t intended to diagnose, treat, cure, or prevent any disease.

Abstract: This article discusses the symptoms, dangers and health problems related to the yeast infection. This infection is more common among women. however, there are still many women who have no knowledge of this medical problem. it is important to know the symptoms, dangers and diseases related to infection, “yeast” to treat it on time. it is also necessary to determine the various causes of this disease to prevent it before it happens.

What is the infection, “yeast” or genital candidiasis?Candidiasis, also known as vulvovaginal candidiasis or VVC, is a common fungal infection that occurs when there is overgrowth of fungus called Candida. Candida is always present in the body in small amounts. however, when an imbalance occurs, for example, changes in the acidity of the vagina or hormonal balance changes, Candida can multiply. When this happens, symptoms of candidiasis.

Not many women are familiar with the term infection “yeast”. however, they are probably aware, or have previously experienced the symptoms of this condition. the first three signs of having yeast infections include itching, burning, pain, and discharge.

ItchIt occurs in any part of the skin or body and is usually caused by an infestation of foreign organisms such as fungi or bacteria in a particular area of ​​the body. in the case of yeast infection, the affected part is the vaginal and surrounding areas. the infection can cause intense itching, rashes or manifests in redness and usually then comes the scratching action.

BurningAnother indication is a burning sensation or pain in that particular area to urinate. the skin on the woman’s vaginal sores may already contain scratching that, placed in contact with the acidity of the urine can cause pain or a burning sensation. This feeling may be similar to that experienced by having a urinary tract infection, however, occur in different areas of the body.

DownloadsFinally, Yeast Infection No More some women have urinary discharge odorless and white as cheese and other cases to scent starches.

The infection “yeast” in itself is not considered highly dangerous, however, can be very irritating and disturbing, especially among women who are concerned about other responsibilities or tasks. Moreover, like most infections, it is transferable to other persons, including the opposite sex. Certain conditions of the body can make it easy for people to get sick.

Other health problems that are usually associated with infection, “yeast” are urinary tract infections and complications during pregnancy. however, there is a scientific basis and has not yet been demonstrated in studies or denied.

What causes the infection, “yeast”?This genital mycosis caused by a fungus, Candida albicans. the concept is now accepted that this is an STD (Sexually Transmitted Infections), but not always.

“Candidiasis” is a term used to describe the growth and development of the fungus. Under normal circumstances this is a host yeast saprophyte (normal) intestinal tract, oral, vaginal. For certain conditions (overconsumption of antibiotics, hormonal contraceptives, pregnancy, or diets rich in sugars) this fungus becomes single guest in a pathogenic fungus, due to immune system depression, and immunity of the vagina. Candidiasis is a condition that occurs in women of reproductive age.

What are the treatments for yeast infection or candidiasis?the treatment is based ovules and creams containing fungistatic antibiotics: usually all azoles: isoconazole, clotrimazole, tioconazole, econazole, ketoconazole, itraconazole, fluconazole, miconazole, terconazole, Butoconazole, and the Nystatin. they can also indicate oral antifungal. before starting treatment should be ascertained on systemic diseases, prolonged use of antibiotics, drugs, other infections, and the use of douches, now outlawed. During pregnancy it is advisable to use local topical azoles in not less than 7 days.

BioAlliance Pharma SA (Paris:BIO)(Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today announces the achievement of the reserved capital increase and the payment of the €1 million milestone, as provided in the commercialization agreement signed with the Therabel Group for Loramyc® in Europe.

Therabel has actually subscribed for the maximum amount authorized by the General Assembly Meeting of June 29, 2011, i.e. 680.000 new shares, with a 15% premium over the last 20 business days preceding the operation (€3.65 per share).

Moreover, Therabel has finalized end of December 2011 the discussions with the Italian health authorities (Agenzia Italiana del Farmaco) regarding the price and the reimbursement for Loramyc®; publication in the Italian official journal should occur shortly. In this context, BioAlliance will receive from its partner an additional payment indexed on futures sales of Loramyc® in Italy up to a maximum amount of €500.000.

BioAlliance has received more than €11 million (royalties excluded) of which €3.5 million in 2011 since the signature of its partnership agreement with Therabel. An additional €1 million payment is planned end of 2012.

“The approval from the Italian health authorities is a significant step in the European expansion of Loramyc® and opens the way to the product’s commercialization in Italy”, declares Judith Greciet, CEO of BioAlliance Pharma. “These achievements underline the dynamics and the quality of our partnership with Therabel and guarantee our future successes. these funds substantially reinforce our cash reserves and will contribute to develop our R&D programs”.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir® (Acyclovir Lauriad TM) (labialis herpes): Positive phase III final results; registration status

Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products

Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Authorization for Phase III clinical trial

Clonidine LauriadTM (mucositis): Phase II on going

AMEP® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (amf-france.org) or on BioAlliance Pharma SA’s website (bioalliancepharma.com).

Business Wirebusinesswire.com/

Last updated on: 04/01/2012 18:00:06

Systemic candidiasis is an infection which is on the increase, and it is affecting an increasing number of people year after year. the condition is an infection which affects a lot of people without them even realizing it, and they do not know they have it until it is too late. Doctors struggle to diagnose this condition, as symptoms tend to vary from one person to another. Due to there actually being no set symptoms for this condition, there is no way that doctors can diagnose it in its early stages.

There is a vast array of symptoms that are commonly associated with this infection.Systemic candidiasis is commonly known as a yeast infection which affects the intestines. the associated symptoms include problems with the gastro intestinal system such as intestinal cramps, heartburn, constipation, chronic diarrhea, gas or bloating. Other associated symptoms include chronic fatigue and this is especially after consuming food, depression, reduced levels of concentration, poor memory, rectal itching, muscle pains, and allergies that include both air born and food related.

There are other common related symptoms including impotence, prostatitis, memory loss, a feeling of being faint and light headed after eating certain foods, severe pre-menstrual syndrome, aching joints, acne, irritability and reoccurring vaginal infections or urinary infections. all of the mentioned symptoms can happen as part of the fungal type of candida as this fungus can puncture the intestinal wall and allows toxins to leak through and enter into the bloodstream

Once the toxins have escaped into the bloodstream they basically start to poison the intestinal organs including the liver and the brain. the liver will be put under pressure due to the volume of toxins, which are being transported around the body. normally by the time someone has realized that their body is suffering from systemic candidiasis they generally do not feel well. Once you have systemic candidiasis, it is a long road towards recovery and getting back to some sort of normal health.

Food allergies tend to be another common problem, which happen as a result of particles of food entering into the blood stream. in these cases it is again very difficult to diagnose and it is also a very long road to recovery. in most cases the only way of recovering is to avoid the food that causes the problem in the first place.

The anti candida diets are really the first step in getting back to some sort of normal life and this has to be combined with an anti-fungal program. it is very common for both of these diets to also be accompanied with a probiotic supplement. in some cases the patient only has to follow these programs for a couple of months. However, in some cases people have to follow them for a year or even several years.

Systemic candidiasis is not impossible to treat but it does take a lot of very hard work and also an immense amount of dedication. If you are able to follow these plans and stick to them your health will see positive benefits and you will eventually start to get back to some state of normal health.

If you have been struggling with recurring yeast infections for some time, you might have been using a variety of different treatments with the hope that your condition should go away. am i right? The sad thing is, the majority of the treatments you have been using only provide a temporary cure. The reason behind this is which they treat the symptoms and not the basis cause of the infection. And so the main cause of the issue is left untreated waiting for the proper conditions to break out again.

What exactly about natural cures?

Unlike over-the-counter treatments and doctors prescriptions, natural alternatives work with your system. They’ve no chemical additives and therefore the risk of unwanted effects are extremely little to none. The reality is, after using over-the-counter and even doctor’s prescribed meds, your system are certain to get accustomed to them and after a while they will have no influence on your condition.

Can you Cure Candida albicans naturally?

The simple answer is yes. however, let’s dig a little deeper to justify why I say yes. to be able to cure candida albicans, you need candida albicans under control. this is actually the micro organism that is the source if the problem. The greater the organism multiply and occupy the flora of the vagina, the harder severe the symptoms will be.

Removing the candida albicans can be achieved with natural cures. for instance, if you apply sugar free yogurt towards the area, it’s going to produce hydrogen peroxide which will create an environment that’s inhibitory to the candida fungi. doing this everyday for around per week will get rid of the symptoms of your infection.

Another natural cure for yeast infection is tea tree oil. this can be a substance which is used to deal with several types of diseases around the globe. in this case you’ll have to dilute the tea tree oil with a few distill water as it might be too concentrated as is to be placed on the sensitive regions of the vagina. once diluted, you are able to apply the tea tree oil topically or insert in to the vagina through usage of a tampon. do not let it to stay inside the vagina for additional that 30 minutes. doing this treatment for about a week will assist you to eliminate your candida albicans.

As you can see in the above natural cures that candida albicans can indeed be cured naturally. Therefore is you are searching for a natural remedy for candida albicans, try the above mentioned remedies for fast relief of symptoms.

Candidiasis, commonly called yeast infection or thrush, is common fungal infection caused by the Candida species. the most common being Candida Albicans. Under normal circumstances, candida yeasts are usually present in most people, the growth of candida is kept in check by other naturally microorganisms, such as bacteria and other flora. Strong immune system also plays an important role in keeping candida growth balanced. However, due to some reasons, overgrowth may occur and that is when candida causes problems to our health.

Candidiasis is the second most common cause of vaginal irritation or vaginitis. This also occurs in male genitals. Children can be affected too, usually by chronic mouth yeast infections, normally seen around the mouth as white patches. Candidiasis can usually be found in exposed and moist body parts such as the mouth, vagina, folds of skin, nipples during breast feeding, foreskin in men, the ear and in the nostrils. some of the common symptoms of candida infections include severe itching, burning, and soreness, irritation of the vagina and/or vulva, and a whitish or whitish-gray discharge, often with a curd-like appearance.

Some of the common causes of candida overgrowth are:

*External use of irritants (such as some detergents or douches) or internal disturbances (hormonal or physiological) can perturb the normal flora, constituting lactic acid bacteria, such as lactobacilli, and an overgrowth of yeast can result in noticeable symptoms.

*The use of oral contraceptives

*Engaging in vaginal sex immediately and without cleansing after anal sex

*Using lubricants containing glycerin have been found to be causally related to yeast infections.

*Use of antibiotics are also linked to an increased incidence of yeast infections.

*Other secondary causes include hormone replacement therapy, infertility treatments and diet.

Candida infection or candidiasis is commonly treated with antifungal drugs. However, candida infections might be commonly misdiagnosed as bacteria infection and thus antibiotics are prescribed. Antibiotics will worsen the condition as antibiotics will eliminate the friendly bacteria which is the natural candida eliminator.

Treating Candidiasis solely with medication may not give desired results, and other underlying causes require consideration. As an example, oral candidiasis is often linked to the use of inhaled corticosteroids in asthma medication. Patients on long-term inhaled corticosteroids should rinse their mouths after each dose of steroids to counteract this effect. Oral candidiasis can also be the sign of a more serious condition, such as HIV infection, or other immunodeficiency diseases.

You can try these home remedies for candidiasis:

# Increase the consumption of yogurt (which contains lactobacillus), probiotics, acidophilus tablets or salves.

# Try taking some lightly crushed cloves of garlic which contains allicin, an antifungal agent.

# some have used boric acid for treating vaginal infections, by inserting gelcaps filled with boric acid powder into the vagina at bedtime for a few consecutive nights.

# Eat a diet consisting of greens, raw and fresh vegetables may provide some relief.

There are many natural supplements for fighting candida infection in the market. some are known to work very effectively. You have to do your research and make sure that it has no side effects and contains only natural ingredients. go to [provenhealthcare.com/recommends/candidol] for more information on candida natural supplements which have proven to work.

BRUSSELS, Dec. 21, 2011 /PRNewswire via COMTEX/ –UCB today announced the start of the EXXELERATE(TM) study which will evaluate the short- and long-term efficacy of Cimzia® (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira®* (adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

“This head-to-head study is an important milestone. we believe that EXXELERATE(TM) should help to provide additional evidence to support early, informed management decisions for people living with this chronic, progressive disease,” said Professor Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President, UCB.

The primary objectives of the study are to compare the relative efficacy of the two anti-TNF therapies during short- and long-term treatment (12 and 104 weeks, respectively).

“While meta-analyses from placebo controlled trials suggest differences in efficacy among anti-TNFs in RA, results from the EXXELERATE(TM) study should help to provide additional insights to support the current lack of head-to-head data and to guide treatment decisions,” said Roy Fleischmann, MD, Clinical Professor of Medicine, The University of Texas South Western Medical Center, Dallas, Texas, US. “As recent guidelines on biological agents recommend rapid treatment to target for RA patients, it is also timely for EXXELERATE(TM) to explore the comparative long term benefits of anti-TNF therapies, related to early response-driven treatment decisions.”

The European League Against Rheumatism (EULAR) and the international Treat-to-Target Expert Committee recommend appropriate therapeutic adaptation of disease-modifying anti-rheumatic drugs to reach targets of remission or low disease activity within three to six months of starting treatment.

Persistent active disease is a predisposing factor of subsequent disease severity, such as progressive joint damage, irreversible disability and increased mortality. Therefore, stopping inflammation rapidly can be an important therapeutic goal and studies have shown that achieving control of disease activity, ideally rapid control, has led to improved long-term outcomes for patients with RA.

EXXELERATE(TM) is a multi-center, single-blind, randomized, parallel-group study which will randomize patients to either certolizumab pegol plus MTX or adalimumab plus MTX. After 12 weeks, patients who respond will continue their initial treatment, whereas non-responders will switch to the alternative treatment arm until study end at 104 weeks. By including a week 12 response-based therapeutic decision, EXXELERATE(TM) aims to assess the impact of early response-driven treatment on long-term (104 weeks) clinical and patient outcomes. The study aims to enroll approximately 900 adult patients with moderate to severe RA in multiple geographies including the US, Canada and Europe, who have inadequately responded to MTX and who have not previously received anti-TNF treatment. The headline results from the study are expected in 2016.

Cimzia® is indicated for the treatment of adult patients with moderately to severely active RA. serious and sometimes fatal side effects have been reported with Cimzia®, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with Cimzia®. Lymphoma and other malignancies also have been reported in children and adolescents. Cimzia® is not indicated for use in pediatric patients.

* Humira® is a registered trademark of Abbott

About CIMZIA® Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. this cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia® for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderately to severely active rheumatoid arthritis. Cimzia® in combination with MTX, is approved in the EU for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying antirheumatic drugs (DMARDs) including MTX. Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A.

Cimzia® (certolizumab pegol) in the US important safety information

Risk of serious Infections and Malignancy

Patients treated with CIMZIA are at an increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before CIMZIA use and during therapy. Treatment for latent infection should be initiated prior to CIMZIA use.

Invasive fungal infections, including histoplasmosis , coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is not indicated for use in pediatric patients.

Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.

Treatment with CIMZIA should not be initiated in patients with an active infection, including clinically important localized infections. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (e.g. corticosteroids or methotrexate) may be at a greater risk of infection. Patients who develop a new infection during treatment with CIMZIA should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for immunocompromised patients, and appropriate antimicrobial therapy should be initiated. Appropriate empiric antifungal therapy should also be considered while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are endemic.

MalignanciesDuring controlled and open-labeled portions of CIMZIA studies of Crohn’s disease and other diseases, malignancies (excluding non-melanoma skin cancer) were observed at a rate of 0.5 per 100 patient-years among 4,650 CIMZIA-treated patients versus a rate of 0.6 per 100 patient-years among 1,319 placebo-treated patients. In studies of CIMZIA for Crohn’s disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients. this is approximately 2-fold higher than expected in the general population. Patients with RA, particularly those with highly active disease, are at a higher risk for the development of lymphoma. The potential role of TNF blocker therapy in the development of malignancies is not known.

Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy less than or equal to 18 years of age), of which CIMZIA is a member. Approximately half of the cases were lymphoma (including Hodgkin’s and non-Hodgkin’s lymphoma, while the other cases represented a variety of different malignancies and included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.

Most of the patients were receiving concomitant immunosuppressants.

Cases of acute and chronic leukemia have been reported with TNF-blocker use. even in the absence of TNF-blocker therapy, patients with RA may be at a higher risk (approximately 2-fold) than the general population for developing leukemia.

Heart FailureCases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA has not been formally studied in patients with CHF. Exercise caution when using CIMZIA in patients who have heart failure and monitor them carefully.

HypersensitivitySymptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following CIMZIA administration. If such reactions occur, discontinue further administration of CIMZIA and institute appropriate therapy.

Hepatitis B ReactivationUse of TNF blockers, including CIMZIA, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating CIMZIA therapy. Exercise caution in prescribing CIMZIA for patients identified as carriers of HBV, with careful evaluation and monitoring prior to and during treatment. In patients who develop HBV reactivation, discontinue CIMZIA and initiate effective anti-viral therapy with appropriate supportive treatment.

Neurologic ReactionsUse of TNF blockers, including CIMZIA, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA. Exercise caution in considering the use of CIMZIA in patients with these disorders.

Hematologic ReactionsRare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with CIMZIA. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on CIMZIA. consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities.

Drug InteractionsAn increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept. Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of CIMZIA in these combinations. Therefore, the combination of CIMZIA with anakinra, abatcept, rituximab, or natalizumab is not recommended. Interference with certain coagulation assays has been detected in patients treated with CIMZIA. there is no evidence that CIMZIA therapy has an effect on in vivo coagulation. CIMZIA may cause erroneously elevated aPTT assay results in patients without coagulation abnormalities.

AutoimmunityTreatment with CIMZIA may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.

ImmunizationsDo not administer live vaccines or attenuated vaccines concurrently with CIMZIA.

Adverse ReactionsIn controlled Crohn’s clinical trials, the most common adverse events that occurred in greater than or equal to 5% of CIMZIA patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% CIMZIA, 13% placebo), urinary tract infection (7% CIMZIA, 6% placebo), and arthralgia (6% CIMZIA, 4% placebo). The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for CIMZIA and 7% for placebo.

In controlled RA clinical trials, the most common adverse events that occurred in greater than or equal to 3% of patients taking CIMZIA 200 mg every other week with concomitant methotrexate (n=640) and more frequently than with placebo with concomitant methotrexate (n=324) were upper respiratory tract infection (6% CIMZIA, 2% placebo), headache (5% CIMZIA, 4% placebo), hypertension (5% CIMZIA, 2% placebo), nasopharyngitis (5% CIMZIA, 1% placebo), back pain (4% CIMZIA, 1% placebo), pyrexia (3% CIMZIA, 2% placebo), pharyngitis (3% CIMZIA, 1% placebo), rash (3% CIMZIA, 1% placebo), acute bronchitis (3% CIMZIA,1% placebo), fatigue (3% CIMZIA, 2% placebo). Hypertensive adverse reactions were observed more frequently in patients receiving CIMZIA than in controls. these adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and non-steroidal anti-inflammatory drugs. Patients receiving CIMZIA 400mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving CIMZIA 200mg every other week. The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 5% for CIMZIA and 2.5% for placebo.

please consult the full prescribing information in relation to other side effects, full safety and prescribing information: cimzia.com

for further information

Antje Witte, Investor Relations UCBT +32.2.559.9414,

France Nivelle, Global Communications, UCBT +32.2.559.9178,

Eimear O’Brien, Director, Brand CommunicationsT +32.2.559.9271,

Andrea Levin, Senior PR Manager, US Communications and Public RelationsT +1.770.970.8352,

About UCBUCB, Brussels, Belgium ( ucb.com ) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. with more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol:UCB).

Forward-looking statements this press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

there is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Copyright (C) 2011 PR Newswire. All rights reserved

THE term AIDS is an acronym that stands for “acquired Immune Deficiency Syndrome”. It is acquired because the victims do not inherit the condition, but contract it. Immune deficiency means that the victim’s natural bodily 

defense mechanisms are unable to function properly, and “syndrome” refers to the combination of different abnormalities or diseases making up this condition.

AIDS is a complex of diseases and symptoms resulting from unexplained immune deficiency; caused by a retrovirus, culminating in a “mixed-bag” of life-threatening opportunistic infections, which invariably results in death. The retrovirus that causes AIDS is known as Human Immunodeficiency Virus (HIV) with types I, II, and III already isolated.

Although there have been wide speculations and insinuations as to the origin of the virus (HIV), the fact still remains that the first cases of AIDS were diagnosed in North America, Europe and Central Africa about the same time in 1981. since then, cases are being reported all over the world and most countries now have people with “full-blown” AIDS as well as carriers infected with the virus. It occurs in about 1 to 10% of the population and the incubation period is 4 to 10 years.

The virus has been isolated mostly from semen, vaginal secretion and blood. It is generally believed to be contracted through sexual intercourse, transfusion of contaminated blood, use of un-sterile instruments such as needles, blades and catheters, trans-placental infection, organ transplant, tattooing and circumcision as well as breast-feeding.

The major characteristic feature of AIDS is weight loss of about 10kg within 1 month without a known cause. Other symptoms include chronic diarrhoea, persistent cough, skin infections, oro-pharyngeal candidiasis, swollen lymph glands and night sweating.

Prevention of AIDS is achieved through avoidance of casual sex, and other factors that may predispose to HIV infection; as well as sterile procedures in clinico-surgical practices.

Treatment and Control

Before recommending our treatment and control packages for HIV/ AIDS, it is pertinent to ask the following questions:

1.    why do outbreaks of serious infectious diseases leave some people devastated and others free? 

2.    If some people are known to be carriers and could go around with the virus for up to 15 years before they physically breakdown, couldn’t there be ways of helping to cleanse the virus from the system before it manifests?

3.    are the sufferer’s thoughts, aspirations and living habits not affecting the disease cycle as well as response to treatment?

If yes, then in Holistic Lifecare, we are committed to total cure of HIV/AIDS sufferers when they have just been tested and diagnosed positive, when they are still able to eat, drink and move around on their own, but not when they are expecting their funeral the next day!

The Holistic Natural Remedy being suggested for restoring good health, vitality, and total cure in HIV/AIDS sufferers; is a combination of herbal, nutritional and psycho-social therapies at the appropriate time and in the right proportion. Notable among the useful herbs for HIV/AIDS are Aloe vera, Allium sativum, Harpagophytum zeyheri, Echinacea augustifolia and Zingiber officinale.

For further information and consultation on Holistic Lifecare research and services, especially on Blood Infections, Infertility, Sexually Transmitted Diseases, Chronic Debilitating Conditions as well as mental and social problems, please call  on: 0803-330-3897 or visit: Mosebolatan Holistic Lifecare Centre, Adeyalo Layout, Ogbere-Tioya, off Olorunsogo Express Bridge, Ibadan. Website: holisticlifecare.com. Distance is no barrier, we can send remedies by courier if need be. we also have facilities for accommodation, admission and hospitalization in a serene and homely environment.

The treatment of a Candida albicans yeast infection involves many elements that may, and often will, impact the situation in a particular way. It’s possible that a preferred method of treatment exists that relates to one of these special factors. for many reasons, you really must see a doctor or visit your clinic to get an accurate diagnosis and treatment method. Yet, there are dozens of various types of over-the-counter yeast infection treatments available to anyone. Only one-third of the women in a scientific study had accurately diagnosed their infection as a yeast infection. the other two-thirds misdiagnosed their condition. Don’t you think that is a terrible error rate? 66% were wrong!

The treatment of a yeast infection during pregnancy has to be approached carefully and must involve a doctor’s intervention. OTC medications and self-diagnosis of a yeast infection are some things that a pregnant woman should never do. see your OB/GYN or doctor and get a concise evaluation and treatment plan. It’s pretty certain that during a pregnancy no orally administered drugs will be prescribed.

If you have a vaginal yeast infection, the normal treatment consists of antifungal creams and suppositories. It usually takes about a week for a yeast infection to be successfully treated and eliminated. we may sound like a broken record but, again, if you are pregnant and you feel those first tinglings of an impending yeast infection, call your clinic or doctor and make an appointment. Candidiasis oral (oral thrush) is very common in children, as well as adults. It is not a condition you can treat yourself. It requires the intervention of a pediatrician or medical treatment professional. Vigilance with respect to a child’s health is mandatory, as is a trip to the doctor when a yeast infection is suspected. Oral thrush can be easily treated as long as there are no other medical conditions or complicating factors. when someone has oral thrush, it can be extremely painful to eat or drink. This could cause you to become dehydrated, which is one of the factors that cause a weakened immune system. if this situation arises, then a call to your doctor is in order, and you may be admitted to the hospital for fluid replenishment and stronger treatment.

There are precautions that are indicated, in addition to the proper treatment, if your current yeast infection is a repeat. for instance, if your child has had oral thrush, then be sure to sterilize or wash anything that has come in contact with the child’s mouth. and, if it is necessary for you to breastfeed an infant who has a case of oral thrush, check your nipple area constantly to look for signs that the yeast infection has spread to you. if you find yourself in this situation, a consultation with your doctor is definitely in order. They can give you the correct guidance. It seems that the more you try to educate yourself about the various treatments and symptoms of yeast infections, the more you come to realize that it’s a lot more complicated than it appears. we only bring this up because we have seen that treatments vary so much. Some are an one-time pill that clears your infection up in a week and other treatments last a long time and don’t respond quickly to the treatment. Bacterial vaginosis and Trichomonas vaginalis have similar symptoms to Candidiasis vaginitis, but are entirely different. these are the main reasons we believe it is not wise to diagnose your yeast infection.

Watch Glee Season 3 Episode 9